Below is Validea's guru fundamental report for SEAGATE TECHNOLOGY HOLDINGS PLC (STX). Of the 22 guru strategies we follow, STX rates highest using our Multi-Factor Investor model based on the ...

Seagate Technology (NASDAQ:STX – Get Free Report) was upgraded by research analysts at Benchmark from a “hold” rating to a ...

Below is Validea's guru fundamental report for SEAGATE TECHNOLOGY HOLDINGS PLC (STX). Of the 22 guru strategies we follow, STX rates highest using our Multi-Factor Investor model based on the ...

Investors in Seagate Technology Holdings PLC (Symbol: STX) saw new options become available today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up ...

Seagate Technology (NASDAQ:STX – Get Free Report) had its price target boosted by Citigroup from $120.00 to $125.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” ...

Investors in Seagate Technology Holdings PLC (Symbol: STX) saw new options become available today, for the April 17th expiration. One of the key data points that goes into the price an option ...

Seagate Technology Holdings plc (NASDAQ:STX – Get Free Report) shares gapped up prior to trading on Wednesday after the company announced a dividend. The stock had previously closed at $101.25, but ...

Seagate Technology Holdings plc STX stock has slipped 9.9% in the past month compared with the industry and S&P 500 Composite’s decline of 4.2% and 2.7%, respectively. The stock fell 1% in the ...

The upcoming report from Seagate (STX) is expected to reveal quarterly earnings of $1.88 per share, indicating an increase of 1466.7% compared to the year-ago period. Analysts forecast revenues of ...

We recently compiled a list of the 10 Important AI News on Investor Radars. In this article, we are going to take a look at ...

Seagate Technology (NASDAQ:STX – Get Free Report) had its price target upped by research analysts at Bank of America from ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...